---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-23-000125"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2023-09-12T23:59:59+00:00"
generated_at: "2026-06-10T21:17:42.626709+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Humacyte reports positive Phase 2/3 HAV trauma trial; BLA planned Q4 2023

## Summary
- 30-day secondary patency 90.2% (extremity pts) vs 81.1% synthetic graft benchmark.
- Amputation rate 9.8% and infection rate 2.0%, both lower than synthetic graft rates.
- BLA filing for HAV in extremity vascular trauma expected in Q4 2023.
- No unexpected safety signals; results from Ukraine cohort also positive.
- HAV has RMAT designation, may allow priority review and no post-approval study.

## SEC filing metadata
- accession: 0001818382-23-000125
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2023-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838223000125/0001818382-23-000125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838223000125/huma-20230912.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-23-000125
- JSON: https://secwatch.observer/filing/0001818382-23-000125.json
- Plain text: https://secwatch.observer/filing/0001818382-23-000125.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.